Lyon, June 15th, 2015 - Adocia (Euronext Paris : FR0011184241 – ADOC) announces today that, following the review of the Euronext Paris Stock Exchange Indices on June 5th, 2015, the “Conseil Scientifique des Indices” made the decision to admit Adocia to the list of companies in the CAC Mid 60 and SBF 120 indices (“Société des Bourses Françaises”).

This decision will take effect at the opening of trading on Monday 22nd of June 2015.

The CAC Mid 60 index includes 60 companies of national and European importance. It represents the 60 largest French equities beyond the CAC 40 and the CAC Next 20. It includes the 60 most liquid stocks listed in Paris among the 200 first French capitalizations. This total of 120 companies compose the SBF 120.

"After the recent integration of Adocia to the Label Tech 40, we are delighted to have been selected to be part of these more global indices, recognition of our level of capitalization, liquidity and float. Joining these indices contributes to elevating Adocia’s international visibility and supporting our efforts to develop our innovative products.” said Gérard Soula, Chief Executive Officer of Adocia.

About Adocia

To be a global leader in the innovative delivery of insulins and therapeutic proteins
Adocia is a clinical stage biotechnology company that specializes in the development of innovative formulations of already approved therapeutic proteins. It has a particularly strong expertise in the field of insulins. Adocia’s proprietary BioChaperone® technological platform is designed to enhance the effectiveness and safety of therapeutic proteins and their ease of use for patients.

In December 2014, Adocia signed a partnership with Eli Lilly for the development and commercialization of its new formulation of insulin lispro, BioChaperone Lispro, previously tested successfully in two phase Ib/IIa studies.

Adocia will continue to develop its fast-acting human insulin formulation internally. Two clinical studies are planned over 2015, a post-meal glucose control study with HinsBet U100 and a PK/PD study with HinsBet U500. Adocia is also actively continuing the development of its BioChaperone Combo, a unique combination of insulin Glargine, the gold-standard of basal insulin and insulin lispro, a fast-acting insulin analog. Two Phase IIa clinical studies are scheduled for the second quarter 2015, one which is a glycemic control after a standardized meal with type 1 diabetic patients, the other clinical study is about pharmacodynamics in euglycemic clamp with type 2 diabetic patients. A dose-response clinical study in type 1 diabetic patients is also scheduled for the fourth quarter of 2015.

In addition, Adocia launched a phase III clinical study in India on its product based on PDGF-BB for treatment of the diabetic foot ulcer (BioChaperone PDGF-BB) in August 2014.
Adocia has extended its activities to the formulation of monoclonal antibodies, which are gold-standard biologics for the treatment of various chronic pathologies (cancer, inflammation, etc.). Adocia is engaged in collaborative programs with two major pharmaceutical companies in this field.

**Fighting cancer with targeted treatments**

DriveIn® is a nanotechnology which is intended to significantly improve delivery of active compounds into cancer cells. This new proprietary platform constitutes an exceptional opportunity to enter the oncology market by improving the efficacy of both already approved treatments and novel proprietary molecules.

« Innovative medicine for everyone, everywhere »

Adocia’s therapeutic innovations aim to provide solutions in a profoundly changing global pharmaceutical and economic context, characterized by (i) an increased prevalence and impact of the targeted pathologies, (ii) a growing and ageing population, (iii) a need to control public health expenditures and (iv) an increasing demand from emerging countries.

Adocia is listed on the regulated market of Euronext in Paris (ISIN: FR0011184241; Reuters/Bloomberg ticker: ADOC, ADOC.PA, ADOC.FP) and is included in the Next Biotech and Tech 40 indexes.

American Depositary Receipts representing Adocia common stock are traded on the US OTC market under the ticker symbol ADOCY.

For more information, visit: [www.adocia.com](http://www.adocia.com)

For more information please contact:

<table>
<thead>
<tr>
<th>Adocia</th>
<th>Adocia Press Relations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gérard Soula</td>
<td>ALIZE RP</td>
</tr>
<tr>
<td>Chairman and CEO of Adocia</td>
<td>Caroline Carmagnol</td>
</tr>
<tr>
<td><a href="mailto:contactinvestisseurs@adocia.com">contactinvestisseurs@adocia.com</a></td>
<td><a href="mailto:caroline@alizerp.com">caroline@alizerp.com</a></td>
</tr>
<tr>
<td>Tel.: +33 4 72 610 610</td>
<td><a href="mailto:adocia@alizerp.com">adocia@alizerp.com</a></td>
</tr>
</tbody>
</table>

Tel.: + 33 1 44 54 36 61
Disclaimer
This press release contains certain forward-looking statements concerning Adocia and its business. Such forward-looking statements are based on assumptions that Adocia considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the 'Risk Factors' section of the Reference Document registered by the Autorite des marchés financiers on April 30, 2015 under number R.15-032 (a copy of which is available on www.adocia.com) and to the development of economic conditions, financial markets and the markets in which Adocia operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Adocia or not currently considered material by Adocia. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Adocia to be materially different from such forward-looking statements.

This press release and the information contained herein do not constitute an offer to sell or the solicitation of an offer to buy Adocia shares in any jurisdiction.